In vitro and in vivo activity of EDTA and antibacterial agents against the biofilm of mucoid Pseudomonas aeruginosa

Infection

Volumn 45, Issue 1, 2017, Pages 23-31

  Liu, Zhenqiu ^a,b,c   Lin, Yaying ^d   Lu, Qi ^a,b,c   Li, Fang ^a,b,c   Yu, Jialin ^a,b,c   Wang, Zhengli ^a,b,c   He, Yu ^a,b,c   Song, Chao ^a,b,c  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c Chongqing Intl Science and Technology Cooperation Center for Child Development and Disorders   (China)

^d Maternal and Child Health Hospital of Xiamen City Reproductive Medicine Center   (China)

Author keywords

Antibacterial agents; Biofilm; Ethylenediamine tetraacetic acid; Pseudomonas aeruginosa

Indexed keywords

AMPICILLIN; BACTERIAL POLYSACCHARIDE; CIPROFLOXACIN; EDETIC ACID; GENTAMICIN; ANTIINFECTIVE AGENT;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIAL LOAD; BACTERIAL VIABILITY; BACTERICIDAL ACTIVITY; BIOFILM; COLONY FORMING UNIT; CONTROLLED STUDY; DIFFUSION; DRUG POTENTIATION; ENTROPY; EXPERIMENTAL GUINEA PIG; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG INFECTION; LUNG PARENCHYMA; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GUINEA PIG; PNEUMONIA, BACTERIAL; PSEUDOMONAS INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOFILMS; DISEASE MODELS, ANIMAL; EDETIC ACID; GUINEA PIGS; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84969164723     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-016-0905-z     Document Type: Article

References (41)

1. Bauer TT, Torres A, Ferrer R, Heyer CM, Schultze-Werninghaus G, Rasche K. Biofilm formation in endotracheal tubes. association between pneumonia and the persistence of pathogens. Monaldi Arch Chest Dis. 2002;57:84–7.
2. Ohgaki N. Bacterial biofilm in chronic airway infection. Kansenshogaku Zasshi. 1994;68:138–51.
3. Kobayashi H. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am J Med. 1995;99:26S–30S.
4. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature. 2000;407:762–4. doi:10.1038/35037627.
5. Stiver HG, Zachidniak K, Speert DP. Inhibition of polymorphonuclear leukocyte chemotaxis by the mucoid exopolysaccharide of Pseudomonas aeruginosa. Clin Invest Med. 1988;11:247–52.
6. Prince AS. Biofilms, antimicrobial resistance, and airway infection. N Engl J Med. 2002;347:1110–1. doi:10.1056/NEJMcibr021776.
7. Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol. 2004;42:1915–22.
8. O’Loughlin CT, Miller LC, Siryaporn A, Drescher K, Semmelhack MF, Bassler BL. A quorum-sensing inhibitor blocks Pseudomonas aeruginosa virulence and biofilm formation. Proc Natl Acad Sci USA. 2013;110:17981–6. doi:10.1073/pnas.1316981110.
9. Banin E, Brady KM, Greenberg EP. Chelator-induced dispersal and killing of Pseudomonas aeruginosa cells in a biofilm. Appl Environ Microbiol. 2006;72:2064–9. doi:10.1128/AEM.72.3.2064-2069.2006.
10. Vaara M. Agents that increase the permeability of the outer membrane. Microbiol Rev. 1992;56:395–411.
11. Hancock RE. Alterations in outer membrane permeability. Annu Rev Microbiol. 1984;38:237–64. doi:10.1146/annurev.mi.38.100184.001321.
12. Delcour AH. Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta. 2009;1794:808–16. doi:10.1016/j.bbapap.2008.11.005.
13. Chaudhary M, Patnaik SK, Payasi A. Evaluation of different drugs in down-regulation of efflux pump genes expression in methicillin-resistant staphylococcus aureus strains. Am J Infect Dis. 2014;10:184–9.
14. Chaudhary M, Payasi A. Ethylenediaminetetraacetic acid: a non antibiotic adjuvant enhancing Pseudomonas aeruginosa susceptibility. Afr J Microbiol Res. 2012;6:6799–804.
15. Finnegan S, Percival SL. EDTA: an antimicrobial and antibiofilm agent for use in wound care. Adv Wound Care (New Rochelle). 2015;4:415–21. doi:10.1089/wound.2014.0577.
16. Gotthelf LN. Diagnosis and treatment of otitis media in dogs and cats. Vet Clin N Am Small Anim Pract. 2004;34:469–87. doi:10.1016/j.cvsm.2003.10.007.
17. Kotsakis GA, Lan C, Barbosa J, Lill K, Chen R, Rudney J, Aparicio C. Antimicrobial agents used in the treatment of peri-implantitis alter the physicochemistry and cytocompatibility of titanium surfaces. J Periodontol. 2016;28:1–20. doi:10.1902/jop.2016.150684.
18. Lebeaux D, Leflon-Guibout V, Ghigo JM, Beloin C. In vitro activity of gentamicin, vancomycin or amikacin combined with EDTA or l-arginine as lock therapy against a wide spectrum of biofilm-forming clinical strains isolated from catheter-related infections. J Antimicrob Chemother. 2015;70:1704–12. doi:10.1093/jac/dkv044.
19. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005;49:1306–11. doi:10.1128/AAC.49.4.1306-1311.2005.
20. Valgas C, Machado de Souza S, Smania EFA, Smania A, Jr. Screening methods to determine antibacterial activity of natural products. Braz J Microbiol. 2007;38:369–80.
21. Sanchez-Gomez S, Lamata M, Leiva J, Blondelle SE, Jerala R, Andra J, Brandenburg K, Lohner K, Moriyon I, Martinez-de-Tejada G. Comparative analysis of selected methods for the assessment of antimicrobial and membrane-permeabilizing activity: a case study for lactoferricin derived peptides. BMC Microbiol. 2008;8:196. doi:10.1186/1471-2180-8-196.
22. Rabe T, Mullholland D, van Staden J. Isolation and identification of antibacterial compounds from Vernonia colorata leaves. J Ethnopharmacol. 2002;80:91–4.
23. Berche P, Gaillard JL, Richard S. Invasiveness and intracellular growth of Listeria monocytogenes. Infection. 1988;16:S145–8.
24. Strathmann M, Wingender J, Flemming HC. Application of fluorescently labelled lectins for the visualization and biochemical characterization of polysaccharides in biofilms of Pseudomonas aeruginosa. J Microbiol Methods. 2002;50:237–48.
25. Beyenal H, Lewandowski Z, Harkin G. Quantifying biofilm structure: facts and fiction. Biofouling. 2004;20:1–23. doi:10.1080/0892701042000191628.
26. Guo SY, Sheng-Qi LI, Liu Y, Sun JM. An intrapulmonary biofilm model of Pseudomonas aeruginosa. Chin J Microbiol Immunol. 2003;23:292–5.
27. Otani T, Katami K, Une T, Osada Y, Ogawa H. Nonbacteremic Pseudomonas pneumonia in immunosuppressed guinea pigs. Microbiol Immunol. 1982;26:67–76.
28. Buckley LM, McEwan NA, Nuttall T. Tris-EDTA significantly enhances antibiotic efficacy against multidrug-resistant Pseudomonas aeruginosa in vitro. Vet Dermatol. 2013;24:519-e122. doi:10.1111/vde.12071.
29. Matsukawa T, Ikeda S, Imai H, Yamada M. Alleviation of the two-cell block of ICR mouse embryos by polyaminocarboxylate metal chelators. Reproduction. 2002;124:65–71.
30. Alakomi HL, Saarela M, Helander IM. Effect of EDTA on Salmonella enterica serovar Typhimurium involves a component not assignable to lipopolysaccharide release. Microbiology. 2003;149:2015–21. doi:10.1099/mic.0.26312-0.
31. Wooley RE, Jones MS. Action of EDTA-Tris and antimicrobial agent combinations on selected pathogenic bacteria. Vet Microbiol. 1983;8:271–80.
32. Al-Azemi A, Fielder MD, Abuknesha RA, Price RG. Effects of chelating agent and environmental stresses on microbial biofilms: relevance to clinical microbiology. J Appl Microbiol. 2011;110:1307–13. doi:10.1111/j.1365-2672.2011.04983.x.
33. Lambert RJ, Hanlon GW, Denyer SP. The synergistic effect of EDTA/antimicrobial combinations on Pseudomonas aeruginosa. J Appl Microbiol. 2004;96:244–53.
34. Cavaliere R, Ball JL, Turnbull L, Whitchurch CB. The biofilm matrix destabilizers, EDTA and DNaseI, enhance the susceptibility of nontypeable Hemophilus influenzae biofilms to treatment with ampicillin and ciprofloxacin. Microbiologyopen. 2014;3:557–67. doi:10.1002/mbo3.187.
35. Zenga J, Gagnon PM, Vogel J, Chole RA. Biofilm formation by otopathogenic strains of Pseudomonas aeruginosa is not consistently inhibited by ethylenediaminetetraacetic acid. Otol Neurotol. 2012;33:1007–12. doi:10.1097/MAO.0b013e31825f249e.
36. Farca AM, Piromalli G, Maffei F, Re G. Potentiating effect of EDTA-Tris on the activity of antibiotics against resistant bacteria associated with otitis, dermatitis and cystitis. J Small Anim Pract. 1997;38:243–5.
37. Chauhan A, Lebeaux D, Ghigo JM, Beloin C. Full and broad-spectrum in vivo eradication of catheter-associated biofilms using gentamicin-EDTA antibiotic lock therapy. Antimicrob Agents Chemother. 2012;56:6310–8. doi:10.1128/AAC.01606-12.
38. Sarkisova S, Patrauchan MA, Berglund D, Nivens DE, Franklin MJ. Calcium-induced virulence factors associated with the extracellular matrix of mucoid Pseudomonas aeruginosa biofilms. J Bacteriol. 2005;187:4327–37. doi:10.1128/JB.187.13.4327-4337.2005.
39. Banin E, Vasil ML, Greenberg EP. Iron and Pseudomonas aeruginosa biofilm formation. Proc Natl Acad Sci USA. 2005;102:11076–81. doi:10.1073/pnas.0504266102.
40. Hachem R, Bahna P, Hanna H, Stephens LC, Raad I. EDTA as an adjunct antifungal agent for invasive pulmonary aspergillosis in a rodent model. Antimicrob Agents Chemother. 2006;50:1823–7. doi:10.1128/AAC.50.5.1823-1827.2006.
41. Sanchez-Fructuoso AI, Blanco J, Cano M, Ortega L, Arroyo M, Fernandez C, Prats D, Barrientos A. Experimental lead nephropathy: treatment with calcium disodium ethylenediaminetetraacetate. Am J Kidney Dis. 2002;40:59–67. doi:10.1053/ajkd.2002.33936.